2/10
01:46 pm
krys
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]
Low
Report
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update [Seeking Alpha]
2/10
08:00 am
krys
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Low
Report
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
2/9
08:00 am
krys
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Low
Report
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
2/7
06:18 am
krys
Krystal Biotech (NASDAQ:KRYS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
Low
Report
Krystal Biotech (NASDAQ:KRYS) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.
2/3
09:06 pm
krys
Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]
Medium
Report
Vyjuvek Growth Powers Krystal Biotech's (KRYS) Huge Upward Analyst Target Price Revision [Yahoo! Finance]
1/30
08:14 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/22
01:21 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Bank of America Corporation from $288.00 to $318.00. They now have a "buy" rating on the stock.
1/19
04:31 am
krys
What Does Wall Street Think About Krystal Biotech (KRYS)? [Yahoo! Finance]
Medium
Report
What Does Wall Street Think About Krystal Biotech (KRYS)? [Yahoo! Finance]
1/18
01:31 am
krys
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year [Yahoo! Finance]
Medium
Report
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year [Yahoo! Finance]
1/16
08:10 am
krys
Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]
Low
Report
Krystal Biotech: Beyond VYJUVEK Commercialization [Seeking Alpha]
1/12
03:58 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at Citigroup Inc. from $320.00 to $336.00. They now have a "buy" rating on the stock.
1/11
01:16 pm
krys
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/11
01:00 pm
krys
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
1/10
07:02 pm
krys
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
Medium
Report
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing [Yahoo! Finance]
1/10
07:02 pm
krys
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]
Medium
Report
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update [Yahoo! Finance]
1/10
02:18 am
krys
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run [Yahoo! Finance]
Medium
Report
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run [Yahoo! Finance]
1/9
02:47 pm
krys
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a "buy" rating on the stock.
1/9
09:02 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/9
07:18 am
krys
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Krystal Biotech (NASDAQ:KRYS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/9
06:10 am
krys
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/8
10:16 pm
krys
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path [Yahoo! Finance]
Medium
Report
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path [Yahoo! Finance]
1/8
04:56 pm
krys
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis [Yahoo! Finance]
Medium
Report
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis [Yahoo! Finance]
1/8
04:01 pm
krys
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Medium
Report
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
1/7
04:05 pm
krys
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Low
Report
Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
1/6
08:02 am
krys
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.
Low
Report
Krystal Biotech (NASDAQ:KRYS) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating.